GlassScriptPhysician profile
Fadi Bailony
NPI 1003965385
$1,944.33
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $50.99 · 2023: $1,436 · 2024: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $511.57 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $225.55 | 2023-2024 | Mounjaro, Jardiance, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $210.02 | 2023-2024 | |
| Abbvie INC. | $129.57 | 2023 | Qulipta, Ubrelvy, Vraylar |
| Abbott Laboratories | $120.05 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $114.48 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $73.50 | 2023-2024 | Nuedexta, Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $46.69 | 2023-2024 | Trintellix |
| Astrazeneca Pharmaceuticals LP | $45.72 | 2023-2024 | Farxiga |
| Amgen INC. | $38.48 | 2023-2024 | Repatha, Otezla |
| Lifescan, INC. | $38.35 | 2023 | |
| Novartis Pharmaceuticals Corporation | $36.63 | 2023 | |
| Tandem Diabetes Care, INC. | $34.61 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Glaxosmithkline, LLC. | $33.34 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $32.35 | 2023 | Cologuard Collection Kit |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.23 | 2023 | Xifaxan |
| Cequr Corporation | $26.17 | 2023 | Cequr Simplicity |
| Corcept Therapeutics | $25.50 | 2024 | Korlym |
| Embecta Corp. | $24.48 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ascensia Diabetes Care US INC. | $22.78 | 2023 | |
| Xeris Pharmaceuticals, INC. | $20.21 | 2023 | Gvoke Hypopen |
| Astellas Pharma US INC | $18.81 | 2023 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.74 | 2024 | Synjardy, Jardiance |
| Mannkind Corporation | $18.29 | 2023 | Afrezza |
| Axsome Therapeutics, INC. | $18.03 | 2023 | Sunosi |
| Biohaven Pharmaceutical Holding Company LTD. | $14.88 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.30 | 2023 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi Bailony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.